Wockhardt's Zaynich Shows Promise Against Drug-Resistant Infections, Global Launch Targeted for 2026
Key Insights
Wockhardt's antibiotic Zaynich (WCK 5222) demonstrates efficacy against multi-drug resistant pathogens, including superbugs, offering a potential breakthrough in combating antimicrobial resistance.
Phase 3 clinical trials for Zaynich are nearing completion, with regulatory filings planned for the US, Europe, and India in the second quarter of next year, targeting potential approvals in early 2026.
Zaynich has shown successful treatment in meningitis (search) cases and compassionate use scenarios, with potential to treat severe infections even in ventilated patients, exhibiting a favorable safety profile.
Wockhardt is poised to launch its novel antibiotic, Zaynich (WCK 5222), globally by mid-2026, targeting drug-resistant infections, including meningitis (search). The drug has demonstrated promising results in Phase 3 clinical trials, showing efficacy against pathogens resistant to many currently available antibiotics.
Clinical Efficacy and Safety
Zaynich has a susceptibility breakpoint of 64 mg/litre for about 10 gram-negative pathogens, significantly higher than recent antibiotics cleared by regulators, which have breakpoints of 2 to 8 mg/litre. According to Wockhardt Chairman Habil F. Khorakiwala, this higher breakpoint indicates greater efficacy in handling different strains. In compassionate use cases, Zaynich has successfully treated meningitis (search) and other severe infections, even in patients on ventilators. Notably, in some instances, the drug was administered for up to 70 days without observed side effects, suggesting a favorable safety profile.
Regulatory Pathway and Market Potential
Wockhardt expects to complete its global Phase 3 clinical trials within the next few months and plans to file for regulatory approval with the US FDA (search), European regulators, and Indian authorities in the second calendar quarter of next year. Approval is anticipated in early 2026, paving the way for a global launch by mid-2026. The company estimates the market potential for Zaynich to be between $5 and $6 billion, with a treatment course priced between $8,000 and $10,000. Khorakiwala noted that in the US alone, approximately 700,000 patients could benefit from the drug, with over 1.1 million potential patients in India.
Addressing Antimicrobial Resistance
Antimicrobial resistance (AMR) is a growing global health threat, with an estimated five million deaths annually attributed to multi-drug resistant infections worldwide, including 1.1 million in India. Zaynich represents a potential breakthrough in treating these infections, particularly those caused by superbugs resistant to most available antibiotics. Khorakiwala emphasized the drug's potential to remain effective for an extended period, offering a crucial tool in the fight against AMR.
Future Plans
While Wockhardt is currently not planning any out-licensing partnerships, the company intends to collaborate with a merchant banker after the completion of clinical trials. The focus remains on securing regulatory approvals and preparing for the global launch of Zaynich in 2026.